(Lexaria Bioscience Corp. stock chart – January to March 2021. Click to enlarge)
When a mining company releases positive drill results, there is an immediate significance for shareholders. In a similar vein, health care stocks can offer much in the way of investor benefit but is seen as more of a “long game” … but when good news through test results is released, each set of results represents an opportunity to move the stock.
In the case of medical play
Lexaria Bioscience Corp. (CSE: LXX, NASDAQ: LEXX, Forum), its stock has moved significantly, with no sign of looking back, while the positive news keeps coming.
In mid-March, LXX announced
extensive progress in five studies focused on the performance of DehydraTECH CBD as a treatment for hypertension.
Three human clinical trials and two animal research trials are part of the Company's 2021 applied research and development (R&D) program. The Company has additional studies under design, to be announced when available. Lexaria’s proprietary DehydraTECH CBD for hypertension studies are being performed by third-party laboratories to ensure study objectivity.
DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream and increases absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to minutes, and even masks unwanted tastes. 18 patents have been granted with more than 60 pending, covering method-of-use, composition-of-matter and medical treatment claims.
These five studies in Lexaria's 2021 DehydraTECH CBD hypertension program are expected to generate data required to further support the validity of using DehydraTECH CBD as a potential anti-hypertension treatment across various prospective applications to the $28 billion (USD) annual hypertension drug market.
Applied R&D programs are essential for the Company to generate confirmatory results and data evidence to improved drug delivery characteristics that enables the pursuit of commercial opportunities and / or corporate relationships. Advancing these applied R&D studies has proven to be a vital early step towards the Company’s goal of establishing commercial relationships with potential industry partners to utilize DehydraTECH within existing product lines or in the development of new product lines.
The global innovator in drug delivery platforms immediately followed this news up with
another announcement - extensive progress made in two of the four planned antiviral drug studies in its 2021 applied R&D program.
These studies used DehydraTECH with antivirals comprised of one SARS-CoV-2 infected human cell culture study (VIRAL-C21-3) and one animal research pharmacokinetic study (VIRAL-A20-2).
The drugs being studied in Lexaria’s 2021 antiviral program not only target SARS-CoV-2 / COVID 19 applications, but also have existing utility across additional infectious disease, allergic and other disease indications.
Lexaria’s Chief Executive Officer, Chris Bunka commented that the Company has seen a very productive start to 2021 so far, with a total of seven studies across various research programs currently underway.
“Lexaria’s applied R&D programs are vital to generate the supportive data required to pursue either regulatory approvals or corporate relationships necessary for commercial launch. We expect great success this year and are eager to report study results as they become available.”
Millions of people die every year from various viruses. The current COVID environment is just the latest in a string of Coronavirus-related events. Viruses will never go away, vaccines will never be 100% effective, and 100% of the population will never have access to them or be willing to take them, which means that drug treatments will always be needed.
Should Lexaria’s technology enhance the delivery characteristics of a number of antiviral drugs, this could provide near-incalculable gains to the Company and its shareholders.
For more information about this Company, visit
lexariabioscience.com.
FULL DISCLOSURE: This is a paid article produced by Stockhouse Publishing.